CalciMedica has secured approximately $49 million through a private placement to fund its pulmonary hypertension (PH) drug development, including a Phase 1b study of Auxora™ in pulmonary arterial hypertension (PAH) with data expected by mid-2027. The financing will also support the advancement of CM5480, an oral CRAC channel inhibitor, toward IND clearance anticipated in mid-2027. This capital injection aims to validate CRAC channel inhibition as a novel treatment targeting both pulmonary vascular remodeling and right ventricular dysfunction, addressing significant unmet needs in PH. The company expects the funds to sustain operations into the second half of 2027 and to generate early clinical proof-of-concept data for its therapies.
Greenlight, a leading cannabis operator, expanded its Ohio presence by opening four new dispensaries and adding in-state manufacturing, reaching the state's maximum allowed eight dispensaries. This move strengthens Greenlight's position in Ohio's lim...
Halper Sadeh LLC is investigating whether shareholders of Element Solutions Inc (ESI), Crinetics Pharmaceuticals (CRNX), and Solstice Advanced Materials (SOLS) are receiving fair treatment in their respective sale and merger transactions. The firm hi...
Investment banks Scotiabank and Bernstein have lowered their price targets for Comcast due to increased competition from new players like SpaceX's Starlink and valuation risks. Comcast is also undergoing a major strategic shift by spinning off its NB...
Elevance Health reported strong Q2 2026 results with earnings per share of $7.45, surpassing analyst estimates of around $6.20. Revenue also exceeded expectations at $49.83 billion, marking consistent quarterly outperformance. The company raised its ...
Lotto.com has appointed Ruxandra Tereanu as Chief Operating Officer and Amanda Coyle as Vice President of Human Resources to strengthen its leadership team amid ongoing expansion in the US digital lottery market. Tereanu brings 13 years of experience...
